Co-Diagnostics awarded $1.2M in funding from NIH for Co-Dx PCR Home platform

Co-Diagnostics has been awarded $1.2M in funding from the National Institutes of Health as part of the Rapid Acceleration of Diagnostics Tech program for completion of its upcoming upper respiratory panel on the Company’s Co-Dx PCR Home testing platform. Co-Diagnostics will utilize the funds from the RADx Tech award to complete development of its flu A/B, COVID-19, and RSV multiplex test, preparatory for that test to begin clinical trials on the Co-Dx PCR Home. The Co-Dx PCR Home is currently undergoing clinical evaluations in anticipation of its submission to the FDA and an initial product launch for a COVID-19 test.